Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 1:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 128 matching trials from the live ClinicalTrials.gov search.
Conditions
Prostate Cancer
Interventions
Aplidin (plitidepsin)
Drug
Lead sponsor
PharmaMar
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
Ann Arbor, Michigan • Seattle, Washington
Conditions
Prostatic Neoplasms
Interventions
VELCADE TM (bortezomib) for Injection
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
4
States / cities
Los Angeles, California • New York, New York • Cleveland, Ohio + 1 more
Conditions
Prostatic Neoplasms
Interventions
PROSTVAC-V/TRICOM, PROSTVAC-F/TRICOM, MDX-010, Sargramostim
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 85 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Adenocarcinoma of the Prostate
Interventions
IMC-A12 (Cixutumumab)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
3
States / cities
San Francisco, California • Portland, Oregon • Seattle, Washington
Completed Phase 2 Interventional Results available

AZD2171 to Treat Prostate Cancer

NCT00436956
Conditions
Prostate Cancer
Interventions
Magnetic Resonance Imaging (DCE-MRI), AZD2171, Prednisone
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer, Androgen-Insensitive Prostatic Cancer, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Anal Cancer, Anal Neoplasm, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma, Malignant Melanoma, Melanoma, Non-small Cell Lung Cancer, Non-small Cell Carcinoma, Small-cell Lung Cancer, Small Cell Carcinoma
Interventions
vobramitamab duocarmazine 2.0 mg (Arm A), vobramitamab duocarmazine 2.7 mg (Arm B), vobramitamab duocarmazine, Abiraterone, Enzalutamide
Biological · Drug
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
14
States / cities
Fountain Valley, California • Los Angeles, California • Jacksonville, Florida + 11 more
Conditions
Prostate Cancer
Interventions
PROSTVAC®-VF/TRICOM™
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
47
States / cities
Homewood, Alabama • Anchorage, Alaska • Fresno, California + 41 more
Conditions
Prostate Cancer
Interventions
docetaxel, sorafenib tosylate
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Castration-Resistant Prostatic Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer, Hormone-Refractory Prostate Cancer
Interventions
GnRH agonist/antagonist, Prednisone, Abiraterone Acetate, Enzalutamide
Biological · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
5
States / cities
Los Angeles, California • Chicago, Illinois • New Orleans, Louisiana + 2 more
Conditions
Prostate Cancer
Interventions
lycopene
Dietary Supplement
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
18
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Atlanta, Georgia + 15 more
Conditions
Prostate Cancer
Interventions
Sagopilone (ZK 219477) + prednisone
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
12
States / cities
Fountain Valley, California • Sarasota, Florida • Baltimore, Maryland + 9 more
Conditions
Prostatic Neoplasms, Neoplasm Metastasis
Interventions
Aflibercept, Placebo (for aflibercept), Docetaxel, Prednisone or Prednisolone
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Bridgewater, New Jersey
Conditions
Prostate Cancer
Interventions
ridaforolimus
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • Houston, Texas + 1 more
Conditions
Prostate Cancer
Interventions
Oral Triamcinalone
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Stanford, California
Conditions
Prostate Cancer
Interventions
docetaxel, epirubicin hydrochloride
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Charleston, South Carolina
Conditions
Castration-Resistant Prostatic Cancer, Metastasis
Interventions
Docetaxel, Ifinatamab Deruxtecan, Opevesostat, Abiraterone, Enzalutamide, Rescue Medication
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
9
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 6 more
Conditions
Castration-Resistant Prostatic Cancer
Interventions
[Lu-177]-PNT2002
Drug
Lead sponsor
Lantheus Medical Imaging
Industry
Eligibility
18 Years and older · Male only
U.S. locations
7
States / cities
Newport Beach, California • Hartford, Connecticut • Jupiter, Florida + 4 more
Conditions
Prostate Cancer
Interventions
Lenalidomide, Docetaxel, Prednisone
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Male only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
2
States / cities
New York, New York
Conditions
Prostate Cancer
Interventions
ABT-751
Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Prostate Cancer
Interventions
CC5013
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
6
States / cities
Berkeley, California • Tampa, Florida • Boston, Massachusetts + 3 more
Conditions
Prostatic Neoplasms
Interventions
Docetaxel, Thalidomide, Prednisone, bevacizumab, polymorphism analysis, immunoenzyme technique, laboratory biomarker analysis, pharmacological study
Drug · Biological · Genetic + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
Calcitriol, Ketoconazole, Laboratory Biomarker Analysis, Pharmacological Study, Therapeutic Hydrocortisone
Dietary Supplement · Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Hormone Refractory Prostate Cancer, Prostate Cancer
Interventions
Phlebotomy
Procedure
Lead sponsor
Immunicon
Industry
Eligibility
18 Years and older · Male only
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Prostate Cancer
Interventions
RAD001, Docetaxel, Bevacizumab
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
2
States / cities
Beverly Hills, California • Los Angeles, California